Findings

What do systematic reviews say?

3 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 3 · 75%Very low 1 · 25%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT to 12 months postRT
Insufficient evidence of a difference in stimulated salivary flow at any time point: end of RT MD -0.09 (95% CI -1.48 to 1.30); 3 months MD 0.38 (95% CI -1.43 to 2.19); 12 months MD 0.82 (95% CI -0.47 to 2.11);…
2 studies
GRADE not reported

Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).

2 findings from 1 review

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine led to higher salivary flow rate (incidence of > 0.1 g saliva/5 min, unstimulated) compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
RR 1.45 [1.13, 1.86]
1 study · 175 participants
GRADE not reported